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the Cochrane Library and PubMed was also conducted using relevant MeSH terms
and text words to identify additional reimbursement and HEOR issues associated
with regenerative medicines. RESULTS:Although considered a nascent field, over
40 HTAs and coverage policies on cellular therapies and regenerative medicines
were available from the key Australian, European and North American HTA
agencies and payers considered in the assessment. Many of HTAs and coverage
policies identified gaps in effectiveness data, particularly the lack of compelling
comparative trials and long-term outcomes, and uncertainty surrounding
cost-effectiveness. CONCLUSIONS: While HTAs and payer policies on regenera-
tive medicines reflected decision factors commonly associated with biopharma-
ceuticals, other key market access factors beyond clinical- and cost-effectiveness
were identified that are specific to this field. These factors include involvement of
multiple reimbursable technologies in cell extraction, processing and administra-
tion; cell handling steps that may engage multiple healthcare budgets; and require-
ments to characterize the value of the entire procedure versus the regenerative
medicine alone. Key considerations for HEOR and market access planning are con-
sidered.
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OBJECTIVES: The diffusion of innovative technologies and specifically the differ-
ence between early and mainstream adopters during the product’s life-cycle (also
known as the chasm/saddle phenomena), has been studied empirically. It has been
demonstrated that given a dual-market structure (e.g. early vs. mainstream adopt-
ers) cost has a substantially higher negative impact on mainstream adoption rate
than on early adoption rate. Previous studies focused primarily on the consumer
electronics industry. We examined whether the phenomena of dual-markets ex-
ists also for medical technologies. METHODS: We analyzed the diffusion of inno-
vation patterns of 11 medical interventions using a recent mathematical model:
the Change of Dominance (CD) model, which analyzes the dynamics between the
early and mainstream adopters. Previous research concluded that influences on
adoption and subsequent diffusion rates are very different for various health cat-
egories, technologies, and geographies. Therefore, our empirical dataset covered
three major medical intervention categories: interventional procedures (e.g. coro-
nary stents), pharmaceuticals (e.g. beta-blockers), and diagnostic technologies (e.g.
CT scans). The dataset was collected from five countries: United States, UK, Korea,
Canada and New Zealand.RESULTS:The CD model has an excellent fit (90%) to all
of the technologies analyzed. Nine of the 11 technologies examined (82%) reached
major market adoption. The median time of change of dominance for these nine
technologies was seven years, very similar to that found for consumer electronics.
The adoption rate at the time of CD is 25%, which is higher than the rate in
consumer electronics markets. The CD time of interventional technologies (e.g.
coronary stents, bypass surgery) was substantially lower (3 vs. 8.5 years) compared
to pharmaceuticals or diagnostic technologies. CONCLUSIONS: The dual market
phenomenon seems to occur in the health care, with similar patterns to the con-
sumer electronics industry. Both technology manufacturers and health planners
should consider these findings when attempting to promote the use of innovative
technologies.
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OBJECTIVES: The literature indicates that the expenditure on orphan drugs will be
increasing over the coming years. The market for orphan drugs has inherent mar-
ket characteristics that sometimes result in high prices. The aim of this study was
to analyse whether awarding orphan designation status has an influence on the
price setting of drugs for rare disease indications. METHODS: To this effect, prices
of designated orphan drugs were compared with other non-designated drugs for
rare disease indications. We identified 28 designated orphan drugs and 16 compa-
rable non-designated drugs for rare disease indications for which we collected
official hospital prices (per defined daily dose) in Belgium in 2010. RESULTS: Or-
phan-designated drugs had a higher median price (€138.56 [interquartile range; IQR
€406.57]) than non-designated drugs (€16.55 [IQR €28.05]) for rare disease indica-
tions (p  0.01). CONCLUSIONS: In conclusion, our results suggest that awarding
orphan designation status in itself is associated with higher prices for drugs for rare
disease indications. In order to gain full insight into orphan drug pricing mecha-
nisms, future research should focus on collecting information about the different
factors influencing orphan drug pricing.
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OBJECTIVES: The pharmaceutical-sector is vital for the society and economy as a
whole. Wholesalers are essential for the distribution-chain because they bridge
time and space between supply and demand. Thus, the study aims to draw a
comprehensive picture of the Pharmaceutical-Wholesale-Industry, outlining its
socio-economic importance compared to other forms of distribution with qualita-
tive and quantitative methods, focusing on Germany, U.K., France, Italy, Spain and
the The Netherlands. METHODS: The necessary data was obtained from different
sources: an online-questionnaire was directed to pharmacies, annual GIRP and
IMS-Health statistics; a questionnaire was directed to GIRP-full-member associa-
tions and Wholesale companies (return rate 81%); and systematical literature re-
search which verified the empirical findings. RESULTS: If pooling of medicines
would not be ensured by Wholesalers, each pharmacy would have to contact each
Manufacturer in order to obtain a complete assortment of medicines. The contin-
uous supply of medicines involves more than 4.5bn transactions between Pharma-
cies, Wholesalers and Manufacturers each year. Without Wholesalers this number
would dramatically increase to 99.4bn transactions per year. On average Whole-
salers are bundling products of 21.84 Manufacturers per delivery. The process-
costs of a several order from Wholesalers are €7.98; from Manufacturer €11.36 (cost
differences of 21.84 supplies from direct sales: €240.11). These additional costs have
to be paid by Manufacturers, Pharmacies and finally by Patients. Furthermore,
Wholesalers pre-finance (Ø €11.5bn for 46d) the entire medicine-market and secure
the cash-flow of the social-insurers. Regarding satisfaction with different distribu-
tion-models, the results of the online-questionnaire show that pharmacists are not
satisfied with the new models (satisfaction Wholesalers: 85.17%; Manufacturer:
39.75%; RWA: 9.50%; DTP: 12.2%). CONCLUSIONS:A reduction in number of Whole-
salers will result in a slower supply of medicines, so the existence of the current
distribution system is vital to the European health care sectors, as Pharmaceutical
Wholesalers help reducing transaction-cost, secure a safe, rapid and continuous
supply of medicines.
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OBJECTIVES: To describe the evolution of biosimilars in the EU Member States (MS)
and to identify the key parameters of the EU biosimilars market dynamics across
countries: time to market entry, prices and market penetration. METHODS: A
quantitative analysis of the EU biosimilar market from 2007 to 2010 was conducted
for 26 EU MS. Data was obtained from European Medicines Agency (EMA) and IMS
MIDAS database, including at country level: Date of market entry of reference
products and biosimilars, unit sales and prices (estimated using official prices) of
existing biosimilars and their respective reference products. Descriptive statistics
were applied to summarize the results. Multivariate regression analysis was ap-
plied to identify statistical associations between: 1) time period between the EMA’s
approval and market entry; 2) market penetration (in monetary value); 3) biosimi-
lars DDD prices and the following independent variables: Pharmaceutical market
value, population, Gross National Income, Price Level Index of medicines, total
expenditure on health as % GNI, total expenditure on health in absolute terms,
government expenditure on health and Generic Price Control, International Price
Comparison, Tendering-like practices, Pharmacists generic substitution, INN pre-
scribing, Procedure for pricing and/or reimbursement decision, and Reference Price
System. RESULTS: The market penetration of biosimilars for the three reference
molecules (somatropin, epoietin and filgrastim) rose from 0.33% in 2007 to 15,52%
in 2010. The multivariate analysis show an association between the price level
index, the total and governmental expenditure on health and an earlier market
entry. CONCLUSIONS: Biosimilars hold a certain promise to help bring down the
cost of biologicals to health systems. Existing evidence in the EU is still limited and
the results do not show a clear pattern of market dynamics, although it becomes
evident that biosimilars will attain smaller price reductions and market penetra-
tion than conventional generics.
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OBJECTIVES: To review economic evidence supporting Rx-to-OTC switches.
METHODS: A systematic search of the EMBASE, Pubmed, ISPOR conference ab-
stracts databases and industry associations websites was conducted. The search
was limited to years 2000–2010 and to North America and European countries. Two
independent reviewers selected eligible studies. RESULTS: The search identified 14
reviews, 12 model publications, 12 database analyses, 5 prospective observational
studies and 11 other. Most articles originated from the US. In 5/6 database analyses
and in 8/9 budget impact models (BIM) that quantified cost consequences of Rx-to-
OTC switching, it was shown to generate savings to healthcare budget holders,
mainly due to Rx-drug acquisition savings. Other key direct savings included
avoided: doctor’s visits to obtain a prescription; emergency room visits or hospi-
talisations due to easier access to an effective or safer therapy. Employers’ benefits
included less time-off work to obtain a prescription and less absenteeism and
presenteeism due to easier access to therapies that improve employee productiv-
ity. Cost consequences of potential misuse due to lack of doctor’s supervision were
frequently acknowledged but rarely quantified. The key factors determining the
extent of savings were: uptake rates of the OTC drug among different types of
populations (i.e. those on Rx drugs, other Rx drugs, OTC-treated, untreated and
undiagnosed), therapeutic area and presence of disreimbursement policies. The
only European BIM is old (2004) and showed potential annual savings of €16.4
billion, assuming that 5% of Rx drugs are switched to the OTC status. However, its
use is limited as it is not specific to any drug/disease area and took a simplistic
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approach to costing and uptake among populations considered. CONCLUSIONS:
Rx-to-OTC switches are a real opportunity to realise savings for budget holders and
productivity gains for employers. More robust economic models are required to
estimate the impact of the switches in Europe.
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OBJECTIVES: Health policy and funding for medications classed as ‘lifestyle’ have
received considerable scrutiny by public health officials as well as politicians. This
has limited public funding and reimbursement for these products in many Euro-
pean countries. A detailed assessment of the variation in payer coverage polices for
lifestyle medications across Europe was conducted. METHODS: The top ‘lifestyle’
indications and associated medications were identified from a literature search
using WHO, PubMed, and ScienceDirect. Selection criteria for the medications in-
cluded being first-to-market in the identified indication or being referenced as the
only off-label treatment for the specified use. Public reimbursement databases (16)
were used to analyze the health technology assessment and reimbursement deci-
sions across European countries (14) for each lifestyle indication. Reimbursement
was classified as favourable (broad/restricted but accessible) or no coverage (not
funded). Where available, justifications for coverage decisions were analysed to
determine the drivers of positive and negative coverage decisions. RESULTS: Life-
style indications where products have achieved high levels of reimbursement in-
clude Dyspepsia (100%), Delaying Menstruation (91%), Restless Leg Syndrome
(87%), and Alcohol Dependence (85%). Those with the worst coverage are Hair Loss
(0%), Hypoactive Sexual Desire Disorder (0%), Erectile Dysfunction (13%), and
Weight Loss (15%). Of the 14 countries researched, those offering the most favour-
able coverage environments for lifestyle treatments were: Belgium (70%), France
(69%), and Austria (69%). The countries with the most limited (no available) cover-
age for lifestyle drug therapies were The Netherlands (13%) and Sweden (25%). Four
general characteristics are associated with better access to market: Cross-Usage in
Other Indications, Areas with High Societal Costs, Diseases that Affect Family Plan-
ning, and Older Therapy Areas. CONCLUSIONS: With pressure on public health
resources, European payers are resistant to the allocation of funds for medications
with lifestyle indications. Despite this, barriers to reimbursement vary substan-
tially across European markets.
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OBJECTIVES: This study seeks to evaluate the impact of the 2011 German health-
care reform (AMNOG) on the global pricing and reimbursement landscape and its
influence, if any, on global market access strategies. METHODS: Key local regula-
tors were interviewed to understand the scope and mechanism of the mandatory
early benefit assessment as well as its implications in terms of pricing and market
access on a national and global level. Primary research consisted of in-depth phone
interviews with six regulatory stakeholders and industry representatives in Ger-
many. Secondary research was based on data from national and regional health-
care authorities, national statistics offices and IHS Global Insight Healthcare and
Pharmaceutical services. RESULTS: AMNOG has put an end to free pricing in Ger-
many by correlating price to added therapeutic benefit scores and opening the
reference pricing system to all patented medicines. The total transparency of the
early benefit assessment and pricing processes can influence prices not only in
Europe but also worldwide. The availability of results from the Federal Joint Com-
mittee (G-BA)’s benefit assessment can affect the pricing and reimbursement sta-
tus of pharmaceuticals worldwide, while international reference pricing can put
downward pressure on prices in at least 22 other countries. CONCLUSIONS: The
German reform will have an impact beyond the country’s borders. Germany has
traditionally been an early pharmaceutical launch market but the end of free pric-
ing and the prospect of lower price levels for products of no and minor-to-moderate
added value may require a complete reconsideration of the optimal launch se-
quence. While AMNOG has revolutionized the pricing and reimbursement land-
scape in Germany, from a global perspective, the reform is not particularly inno-
vative. Germany’s new pricing process is comparable to the French model whereby
perceived degree of innovation directly impacts medicine prices, and comes near
to the Swiss and Austrian models.
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OBJECTIVES: This analysis compares pricing levels across 15 European countries
and 10 therapy areas in 2010. The differences in the price levels are related to
parallel imports and the innovativeness of prescriptions. METHODS: From IMS
PRICING INSIGHTS pricing information for pharmaceutical products is accessed at
the pack level from 15 countries (EU5-Austria-Ireland-Sweden-Norway-Denmark-
Portugal-Greece-Poland-Hungary-Romania) for 2010. Currency rates are fixed at
2010 levels. For the ten therapy areas, product baskets are constructed for the
comparisons: The therapy areas are defined as Anatomic-Therapeutic-Chemical
(ATC) classes at level 2. The top 100 products by sales in the EU5 in these classes
enter the comparisons. Prices are compared at the manufacturer and the public
sales levels. IMS MIDAS identifies imports related to the products in the baskets.
The innovativeness of products is operationalized as the number of months be-
tween the overall first introduction and the introduction in the countries.
RESULTS: The first result is that international drug price comparisons are ex-
tremely sensitive to methodological issues, e.g. sample selection, exchange rates.
Differences in price build-up structures between countries would dominate cross-
country price differences, if not accounted for. Differences between countries exist
at the ex-manufacturer-level, differences between public sales levels tend to be
larger. Price level differences between countries are not consistent across all ana-
lyzed therapy areas. Higher price levels are related to parallel trade rates across
countries and to an earlier access to new pharmaceutical products.CONCLUSIONS:
The analysis shows price differences across countries related to manufacture pric-
ing and regulation structuring the price build-up and taxes. Higher price levels are
linked to an earlier access to innovative products. Parallel trade flows into coun-
tries with higher price levels, usually from countries with lower price levels, caus-
ing scarcities. Differences in economic development and purchasing powers need
to be analyzed to evaluate these differences in pricing levels.
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OBJECTIVES: Value assessment of interventions is conducted in some form or the
other, although the importance given to different domains of decisions differ by
markets. The research is aimed to analyse how perspectives on value assessment
of pharmaceuticals or device interventions vary across regions. The research also
analysed how products at launch increase the chances of approval, shorten time to
reimbursement and remain competitive within the value based pricing agenda.
METHODS: The research involved desk research as well interviews with key influ-
encers and decision makers in major markets beyond Europe. More than 25 tele-
phone or face to face interviews with key stakeholders were conducted. RESULTS:
The research indicated that most countries, other than those that use international
price referencing for setting prices use some form of value assessment method
before fixing the reimbursement level and price of the product. The decisions are
predominantly based on level of unmet needs, severity of diseases, level of inno-
vation, clinical differentiation of the new product against its comparators and how
well the product finds it natural place in the treatment pathway. Many forward
regions claim to use value based assessments to set the price of new launches,
most operate within boundaries. In principal value based pricing should not be
fenced with limitations such as cost/QaLY thresholds, budget impact and price-
volume agreements. However in real life these measures are common in markets
all over the world, the main reason being the limitations in health care budgets.
CONCLUSIONS: It is very challenging to reward products based on their intrinsic
value without introducing other hurdles within the current economic environ-
ment. However it also is critical to reward innovation for future investments in
R&D of new drugs. Health care reforms in the future will raise the bar of innovation
and differentiation making it more challenging for the Pharmaceutical industry
and all those involved in developing new medicines.
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OBJECTIVES: EuSANH is a network of science advisory bodies in Europe. The proj-
ect Eusanh-ISA is funded by 7th framework programme of DG Research. It aims to
improve the quality, effectiveness and efficiency of science advice for health across
Europe. Within this project the objective of this work is to learn about the percep-
tions of policy-makers (PM) and science advise bodies’ (SAB) staff concerning the
relationship between these two groups, and the current use of science advice (SA)
in policy making.METHODS: Two questionnaires were designed targeting both PM
involved in developing health policy (such as government ministers, officials and
senior public servants within national and/or local health services) and senior staff
with extensive experience working in a SAB. The questionnaire was sent to 25 PM
and to 29 SAB staff. Descriptive analysis was carried out. RESULTS: Nineteen PM (3
Belgium, 1 Czech Republic, 1 Lithuania, 2 the The Netherlands, 2 Poland, 1 Roma-
nia, 5 Spain, 3 Sweden and 1 UK) and 25 SAB staff (1 Belgium, 1 Czech Republic, 1
Italy,1 Lithuania, 4 the The Netherlands, 1 Poland, 3 Romania, 11 Spain, and 2 from
Sweden) responded the questionnaire. Factors seen as barriers for the relationship
between PM and SAB are the differences in timing, interest, and difficulties to
translate policy problems into research questions. The communication was seen
as informal. PM and SAB considered that usefulness of SA could be improved with
more clarity, brevity, simplicity and concise reporting. Transparency, indepen-
dency, existence of procedures to adequately deal with conflict of interest, rigor
and systematization of knowledge are factors ranked with highest value.
CONCLUSIONS: Proposals to improve the SA process are “organising regular high
level meetings” and “improve the trust between decisors and researchers”.
PHP37
REGIONAL DRUG EVALUATION IN SPAIN: A COMPARISON AMONG
COMMITTEES
Hernández-Pastor LJ1, Huerta A2
1Glaxosmithkline, Tres Cantos, Madrid, Spain, 2GlaxoSmithKline, Tres Cantos, Madrid, Spain
A339V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
